iBio, Inc. Reports Q3 2025 Financial Results
I'm PortAI, I can summarize articles.
iBio, Inc. reported its Q1 earnings for the quarter ending September 30, 2025, showing a significant increase in cash to $28.1 million, up from $8.6 million, due to a successful public offering. The company incurred a net loss of $5.7 million, with total revenue of $100,000 from partnerships and operating expenses of $6.1 million. iBio focuses on developing AI-driven antibody therapeutics for obesity and cardiometabolic conditions, with plans to advance its IBIO-610 candidate into human trials by early 2027. Management remains optimistic about future growth despite current losses.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments